Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients.

Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue JY, Gatto S, Fernandez-Banet J, Pavlicek A, Velastegui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Janne PA, Olson P, Christensen JG.

Cancer Discov. 2019 Oct 28. pii: CD-19-1167. doi: 10.1158/2159-8290.CD-19-1167. [Epub ahead of print]

PMID:
31658955
2.

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.

Fell JB, Fischer JP, Baer BR, Ballard J, Blake JF, Bouhana K, Brandhuber BJ, Briere DM, Burgess LE, Burkard MR, Chiang H, Chicarelli MJ, Davidson K, Gaudino JJ, Hallin J, Hanson L, Hee K, Hicken EJ, Hinklin RJ, Marx MA, Mejia MJ, Olson P, Savechenkov P, Sudhakar N, Tang TP, Vigers GP, Zecca H, Christensen JG.

ACS Med Chem Lett. 2018 Nov 7;9(12):1230-1234. doi: 10.1021/acsmedchemlett.8b00382. eCollection 2018 Dec 13.

PMID:
30613331
3.

Youth accessing reproductive health services in Malawi: drivers, barriers, and suggestions from the perspectives of youth and parents.

Self A, Chipokosa S, Misomali A, Aung T, Harvey SA, Chimchere M, Chilembwe J, Park L, Chalimba C, Monjeza E, Kachale F, Ndawala J, Marx MA.

Reprod Health. 2018 Jun 19;15(1):108. doi: 10.1186/s12978-018-0549-9.

4.

National Assessment of Data Quality and Associated Systems-Level Factors in Malawi.

O'Hagan R, Marx MA, Finnegan KE, Naphini P, Ng'ambi K, Laija K, Wilson E, Park L, Wachepa S, Smith J, Gombwa L, Misomali A, Mleme T, Yosefe S.

Glob Health Sci Pract. 2017 Sep 28;5(3):367-381. doi: 10.9745/GHSP-D-17-00177. Print 2017 Sep 27.

5.

Role of Food Insecurity in Outbreak of Anthrax Infections among Humans and Hippopotamuses Living in a Game Reserve Area, Rural Zambia.

Lehman MW, Craig AS, Malama C, Kapina-Kany'anga M, Malenga P, Munsaka F, Muwowo S, Shadomy S, Marx MA.

Emerg Infect Dis. 2017 Sep;23(9):1471-1477. doi: 10.3201/eid2309.161597.

6.

Effect of an electronic alert on treatment of skin and soft tissue infections.

Weerahandi H, Lurio J, Pichardo M, Duquaine D, Wu W, Calman N, Weiss D, Marx MA, Wang JJ.

J Med Pract Manage. 2014 Nov-Dec;30(3):203-7.

PMID:
25807626
7.

Age at antiretroviral therapy initiation predicts immune recovery, death, and loss to follow-up among HIV-infected adults in urban Zambia.

Vinikoor MJ, Joseph J, Mwale J, Marx MA, Goma FM, Mulenga LB, Stringer JS, Eron JJ, Chi BH.

AIDS Res Hum Retroviruses. 2014 Oct;30(10):949-55. doi: 10.1089/AID.2014.0046. Epub 2014 Aug 5.

8.

Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.

Arcari JT, Beebe JS, Berliner MA, Bernardo V, Boehm M, Borzillo GV, Clark T, Cohen BD, Connell RD, Frost HN, Gordon DA, Hungerford WM, Kakar SM, Kanter A, Keene NF, Knauth EA, Lagreca SD, Lu Y, Martinez-Alsina L, Marx MA, Morris J, Patel NC, Savage D, Soderstrom CI, Thompson C, Tkalcevic G, Tom NJ, Vajdos FF, Valentine JJ, Vincent PW, Wessel MD, Chen JM.

Bioorg Med Chem Lett. 2013 May 15;23(10):3059-63. doi: 10.1016/j.bmcl.2013.03.012. Epub 2013 Mar 21.

PMID:
23566514
10.

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.

Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW, Knighton DR, Li J, Liu KK, Liu Z, Marx MA, Walls M, Wells PA, Yin MJ, Zhu J, Zientek M.

ACS Med Chem Lett. 2012 Nov 7;4(1):91-7. doi: 10.1021/ml300309h. eCollection 2013 Jan 10.

11.

Trends in hospitalization for community-associated methicillin-resistant Staphylococcus aureus in New York City, 1997-2006: data from New York State's Statewide Planning and Research Cooperative System.

Farr AM, Aden B, Weiss D, Nash D, Marx MA.

Infect Control Hosp Epidemiol. 2012 Jul;33(7):725-31. doi: 10.1086/666329. Epub 2012 May 14.

PMID:
22669235
12.

Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.

Liu KK, Zhu J, Smith GL, Yin MJ, Bailey S, Chen JH, Hu Q, Huang Q, Li C, Li QJ, Marx MA, Paderes G, Richardson PF, Sach NW, Walls M, Wells PA, Baxi S, Zou A.

ACS Med Chem Lett. 2011 Sep 19;2(11):809-13. doi: 10.1021/ml200126j. eCollection 2011 Nov 10. Erratum in: ACS Med Chem Lett. 2012 Feb 9;3(2):170. Baxi, Sangita [added].

13.

Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).

Murphy ST, Alton G, Bailey S, Baxi SM, Burke BJ, Chappie TA, Ermolieff J, Ferre R, Greasley S, Hickey M, Humphrey J, Kablaoui N, Kath J, Kazmirski S, Kraus M, Kupchinsky S, Li J, Lingardo L, Marx MA, Richter D, Tanis SP, Tran K, Vernier W, Xie Z, Yin MJ, Yu XH.

J Med Chem. 2011 Dec 22;54(24):8490-500. doi: 10.1021/jm201019k. Epub 2011 Nov 23.

PMID:
22040023
14.

Community associated methicillin resistant Staphylococcus aureus among New York City men who have sex with men: qualitative research findings and implications for public health practice.

Galindo GR, Casey AJ, Yeung A, Weiss D, Marx MA.

J Community Health. 2012 Apr;37(2):458-67. doi: 10.1007/s10900-011-9463-6.

PMID:
21874581
15.

Feasibility of using a World Health Organization-standard methodology for Sample Vital Registration with Verbal Autopsy (SAVVY) to report leading causes of death in Zambia: results of a pilot in four provinces, 2010.

Mudenda SS, Kamocha S, Mswia R, Conkling M, Sikanyiti P, Potter D, Mayaka WC, Marx MA.

Popul Health Metr. 2011 Aug 5;9:40. doi: 10.1186/1478-7954-9-40.

16.

4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.

Liu KK, Bagrodia S, Bailey S, Cheng H, Chen H, Gao L, Greasley S, Hoffman JE, Hu Q, Johnson TO, Knighton D, Liu Z, Marx MA, Nambu MD, Ninkovic S, Pascual B, Rafidi K, Rodgers CM, Smith GL, Sun S, Wang H, Yang A, Yuan J, Zou A.

Bioorg Med Chem Lett. 2010 Oct 15;20(20):6096-9. doi: 10.1016/j.bmcl.2010.08.045. Epub 2010 Aug 14.

PMID:
20817449
17.

A survey of knowledge, attitudes, and beliefs of medical students concerning antimicrobial use and resistance.

Minen MT, Duquaine D, Marx MA, Weiss D.

Microb Drug Resist. 2010 Dec;16(4):285-9. doi: 10.1089/mdr.2010.0009. Epub 2010 Jul 12.

PMID:
20624097
18.

Epidemiologic investigation and targeted vaccination initiative in response to an outbreak of meningococcal disease among illicit drug users in Brooklyn, New York.

Weiss D, Stern EJ, Zimmerman C, Bregman B, Yeung A, Das D, Dentinger CM, Marx MA, Kornblum J, Lee L, Halse TA, Mayer LW, Hatcher CP, Theodore MJ, Schmink S, Harcourt BH, Zucker JR, Layton M, Clark TA; New York City Meningococcal Investigation Team.

Clin Infect Dis. 2009 Apr 1;48(7):894-901. doi: 10.1086/597257.

PMID:
19231975
19.

2-Morpholino-4-oxo-4,5-dihydro-thio-phene-3-carbonitrile.

Zhu J, Liu KK, Marx MA, Rheingold AL, Yanovsky A.

Acta Crystallogr Sect E Struct Rep Online. 2009 Oct 17;65(Pt 11):o2765. doi: 10.1107/S1600536809041737.

20.

Challenges faced by hospital healthcare workers in using a syndrome-based surveillance system during the 2003 outbreak of severe acute respiratory syndrome in Taiwan.

Shih FY, Yen MY, Wu JS, Chang FK, Lin LW, Ho MS, Hsiung CA, Su IJ, Marx MA, Sobel H, King CC.

Infect Control Hosp Epidemiol. 2007 Mar;28(3):354-7. Epub 2007 Feb 13.

PMID:
17326030
21.

Estimation of HIV prevalence, risk factors, and testing frequency among sexually active men who have sex with men, aged 18-64 years--New York City, 2002.

Manning SE, Thorpe LE, Ramaswamy C, Hajat A, Marx MA, Karpati AM, Mostashari F, Pfeiffer MR, Nash D.

J Urban Health. 2007 Mar;84(2):212-25.

22.

Diarrheal illness detected through syndromic surveillance after a massive power outage: New York City, August 2003.

Marx MA, Rodriguez CV, Greenko J, Das D, Heffernan R, Karpati AM, Mostashari F, Balter S, Layton M, Weiss D.

Am J Public Health. 2006 Mar;96(3):547-53. Epub 2005 Dec 27.

23.

Mass smallpox vaccination and cardiac deaths, New York City, 1947.

Thorpe LE, Mostashari F, Karpati AM, Schwartz SP, Manning SE, Marx MA, Frieden TR.

Emerg Infect Dis. 2004 May;10(5):917-20.

24.

Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity.

Munchhof MJ, Beebe JS, Casavant JM, Cooper BA, Doty JL, Higdon RC, Hillerman SM, Soderstrom CI, Knauth EA, Marx MA, Rossi AM, Sobolov SB, Sun J.

Bioorg Med Chem Lett. 2004 Jan 5;14(1):21-4.

PMID:
14684289
25.

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG.

Cancer Res. 2003 Nov 1;63(21):7301-9.

26.

Association of hepatitis C virus infection with sexual exposure in southern India.

Marx MA, Murugavel KG, Tarwater PM, SriKrishnan AK, Thomas DL, Solomon S, Celentano DD.

Clin Infect Dis. 2003 Aug 15;37(4):514-20. Epub 2003 Jul 29.

PMID:
12905135
27.

The association of health-care use and hepatitis C virus infection in a random sample of urban slum community residents in southern India.

Marx MA, Murugavel KG, Sivaram S, Balakrishnan P, Steinhoff M, Anand S, Thomas DL, Solomon S, Celentano DD.

Am J Trop Med Hyg. 2003 Feb;68(2):258-62.

PMID:
12641422
28.

Evaluation of uremic pruritus at an outpatient hemodialysis unit.

Subach RA, Marx MA.

Ren Fail. 2002 Sep;24(5):609-14.

PMID:
12380906
29.

Total synthesis of (+)-ambruticin S.

Kirkland TA, Colucci J, Geraci LS, Marx MA, Schneider M, Kaelin DE Jr, Martin SF.

J Am Chem Soc. 2001 Dec 12;123(49):12432-3. No abstract available.

PMID:
11734054
30.

Correlation and prediction of phenytoin protein binding using standard laboratory parameters in patients after renal transplantation.

Monaghan MS, Marx MA, Olsen KM, Turner PD, Bergman KL.

Ther Drug Monit. 2001 Jun;23(3):263-7.

PMID:
11360036
31.

Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers.

Sowinski KM, Mueller BA, Grabe DW, Manley HJ, Frye RF, Bailie GR, Marx MA.

Am J Kidney Dis. 2001 Apr;37(4):766-76. Erratum in: Am J Kidney Dis 2001 May;37(5):1111.

PMID:
11273877
32.

Trends in crime and the introduction of a needle exchange program.

Marx MA, Crape B, Brookmeyer RS, Junge B, Latkin C, Vlahov D, Strathdee SA.

Am J Public Health. 2000 Dec;90(12):1933-6.

33.

Comparing new participants of a mobile versus a pharmacy-based needle exchange program.

Riley ED, Safaeian M, Strathdee SA, Marx MA, Huettner S, Beilenson P, Vlahov D.

J Acquir Immune Defic Syndr. 2000 May 1;24(1):57-61.

PMID:
10877496
34.

The poor accuracy of indirect measurements of cadaveric donor kidney weights.

Bunke M, Marx MA, Abul-Ezz S, Almquist G, Barone G, Ketel B.

Clin Transplant. 1999 Jun;13(3):253-9.

PMID:
10383106
35.

Plasma iohexol clearance in automated peritoneal dialysis--its role in adequacy determination.

Marx MA, Shuler CL, Golper TA.

Perit Dial Int. 1998 Sep-Oct;18(5):512-5.

PMID:
9848630
36.

Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations.

Marx MA, Frye RF, Matzke GR, Golper TA.

Am J Kidney Dis. 1998 Sep;32(3):410-4.

PMID:
9740156
37.

Drug dosing adjustments during continuous renal replacement therapies.

Golper TA, Marx MA.

Kidney Int Suppl. 1998 May;66:S165-8. Review. No abstract available.

PMID:
9573596
38.

Drug dosing in acute renal failure: the role of renal replacement therapy in altering drug pharmacokinetics.

Subach RA, Marx MA.

Adv Ren Replace Ther. 1998 Apr;5(2):141-7. Review.

PMID:
9554548
39.

A primer on continuous renal replacement therapy for critically ill patients.

Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ.

Ann Pharmacother. 1998 Mar;32(3):362-75. Review.

PMID:
9533067
40.

Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.

Gardner SF, Marx MA, White LM, Granberry MC, Skelton DR, Fonseca VA.

Ann Pharmacother. 1997 Jun;31(6):677-82.

PMID:
9184704
41.

Pharmacokinetics and cardiovascular effects of ma-huang (Ephedra sinica) in normotensive adults.

White LM, Gardner SF, Gurley BJ, Marx MA, Wang PL, Estes M.

J Clin Pharmacol. 1997 Feb;37(2):116-22.

PMID:
9055137
42.

Diurnal blood pressure variation in kidney-pancreas transplant recipients.

Marx MA, Gardner SF, Ketel BL.

Am J Hypertens. 1996 Aug;9(8):823-7.

PMID:
8862230
43.

Plasma iohexol clearance as an alternative to creatinine clearance for CAPD adequacy studies.

Marx MA, Shuler CL, Tattersall JE, Golper TA.

Kidney Int. 1995 Dec;48(6):1994-7. No abstract available.

44.

Phenytoin and plasmapheresis: importance of sampling times and impact of obesity.

Olsen KM, Marx MA, Monaghan MS, Barnes E, Ackerman BH, Pappas AA.

Ther Drug Monit. 1994 Dec;16(6):624-8.

PMID:
7878706
45.

Pharmaceutical education--a matter of degree.

Marx MA.

Ann Pharmacother. 1992 Jul-Aug;26(7-8):1000-1. No abstract available.

PMID:
1504381
46.

Cefuroxime axetil.

Marx MA, Fant WK.

Drug Intell Clin Pharm. 1988 Sep;22(9):651-8. Review.

PMID:
3063476

Supplemental Content

Support Center